Latest Medtech News
ReEmerge, Inc., a Minnesota-based MedTech company, has launched out of stealth following an oversubscribed $37 million Series A financing round. U.S. Venture Partners and Santé co-led the round, with participation from Oxford Science Enterprises, 415 Capital, IAG Capital Partners, The Vertical Group, and Dendrion Ventures.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The funding will support an upcoming clinical study of the company's Cognitive Network Restoration Therapy (CNRT) in its first indication, traumatic brain injury (TBI), alongside continued technology development and expansion of clinical and regulatory operations. CNRT uses targeted electrical stimulation of the central thalamus, a brain region involved in attention, arousal, and executive function, aiming to activate underactive but still-viable neural circuits rather than help patients compensate around lost function. The approach builds on research led by Dr. Nicholas Schiff of Weill Cornell Medicine, alongside collaborators at Stanford University and the University of Utah, published in Nature Medicine, with foundational intellectual property licensed to ReEmerge through Weill Cornell's Center for Technology Licensing.
ReEmerge's planned study (NCT07730099) is a prospective, single-arm, multicenter trial enrolling up to 40 patients with chronic moderate-to-severe TBI, evaluating cognitive and functional outcomes.
For ReEmerge, the raise and its research pedigree position the company to test whether restorative, rather than purely compensatory, cognitive treatment is achievable years after injury. For the broader MedTech space, the approach adds to a small but growing category of neuromodulation therapies targeting chronic, previously unaddressed neurological deficits, an area where an estimated 27 million people worldwide sustain a TBI each year, many left with lasting cognitive impairment that current rehabilitation-focused care does not fully resolve.
CEO Todd Langevin said the investor support "validates our mission to evolve the recovery trajectory for patients living with impaired cognitive function."
